Disc Medicine Shares Jump 10% in 4 Days Since $450 Million Public Offering
Disc Medicine, Inc. (IRON) closes a $450 million public offering at $75.00 per share, extending its cash runway to 2030 to support bitopertin development.
ALFA USA News
Straight from the SEC filing
Every SEC filing by Disc Medicine, Inc. that we have reported, newest first. Each story links the original filing.
Reference market data from a third-party provider, as of the most recent story (22 Oct 2026). Not a valuation or a recommendation.
Down 3.0% over the last month ($78.93 on 19 Oct → $76.59 on 16 Nov). Daily closing prices. Source: Yahoo Finance.
| 19 Oct | $78.93 |
|---|---|
| 20 Oct | $79.48 |
| 21 Oct | $76.00 |
| 22 Oct | $75.03 |
| 23 Oct | $74.51 |
| 26 Oct | $77.66 |
| 27 Oct | $79.90 |
| 28 Oct | $83.20 |
| 29 Oct | $82.84 |
| 30 Oct | $80.84 |
| 2 Nov | $78.62 |
| 3 Nov | $81.16 |
| 4 Nov | $83.28 |
| 5 Nov | $78.47 |
| 6 Nov | $78.91 |
| 9 Nov | $81.26 |
| 10 Nov | $84.64 |
| 11 Nov | $87.08 |
| 12 Nov | $83.23 |
| 13 Nov | $80.00 |
| 16 Nov | $76.59 |
Disc Medicine, Inc. (IRON) closes a $450 million public offering at $75.00 per share, extending its cash runway to 2030 to support bitopertin development.
Disc Medicine reports that its Phase 3 APOLLO trial met all endpoints, showing a 41.4% PPIX reduction. An NDA resubmission for bitopertin is planned by late 2026.
Track Disc Medicine, Inc. live
Get the next Disc Medicine, Inc. SEC filing seconds after it lands.